Prothena Q4 Earnings Call Highlights

Core Insights - Roche has advanced prasinezumab into the phase 3 PARAISO trial for early Parkinson's disease, aiming to enroll approximately 900 participants with primary completion expected in 2029 [2] - Prothena highlighted significant progress in its clinical pipeline during 2025, with two partner programs moving into phase 3 trials [3] - Prothena's cash burn guidance for 2026 has been sharply reduced, with an expected net cash use of $50–55 million and an anticipated year-end cash balance of approximately $255 million [6][18] Group 1: Clinical Trials and Pipeline Developments - Roche's prasinezumab showed a 40% relative reduction in progression on MDS-UPDRS part 3 versus placebo at 24 months in a subset of participants on stable levodopa, with a nominal p-value of 0.0177 [1] - Prothena's partner programs, including Roche's prasinezumab and Novo Nordisk's coramitug, have advanced to late-stage trials, with primary completions expected around 2029 [7] - The phase 2 trial of coramitug demonstrated a 48% reduction in NT-proBNP versus placebo, with a p-value of 0.0017 [8] Group 2: Financial Performance and Guidance - Prothena reported a net cash used in operations of $163.7 million for 2025, which was favorable compared to its guidance range of $170 million to $178 million [17] - The company ended 2025 with $308.4 million in cash and no debt, and it expects to maintain a cash balance of approximately $255 million by the end of 2026 [6][18] - Prothena's 2026 guidance excludes up to $105 million of potential clinical milestone payments related to coramitug and PRX019 [19] Group 3: Research and Development Focus - Prothena's CYTOPE platform is showing promising preclinical CNS activity, particularly in targeting intracellular disease pathways [5][14] - The company is advancing its anti-amyloid beta antibody program, with prior phase 1 results indicating significant amyloid reductions [16] - Prothena is also conducting a phase 1 trial for PRX019 under its agreement with Bristol Myers Squibb, with completion expected in 2026 [12]